Trial
NCT00751296
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Health Network, Toronto
Collaborators
Celgene
Condition
Chronic Lymphocytic Leukaemia
Intervention
Lenalidomide
Why stopped
Seven years of follow-up \& final analysis done in Dec 2012.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-16